NEW YORK (GenomeWeb News) – Sigma-Aldrich today said it is partnering with the Scripps Research Institute to develop and commercialize new reagents.

The deal, the company said, will "fund research and provide immediate day-of-publication access to [Scripps] researchers' discoveries for the synthesis and analysis of potential drugs," and, further, could "eliminate months from the translation of cutting-edge chemistry into widespread applications for drug discovery."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.